How long does protection from the MV140 vaccine last?

The 9-year follow-up presented at the European Association of Urology Congress 2024 found 54% of patients (n=89) remained UTI-free a mean of 4.5 years after a single 3-month course. The Phase 3 NEJM Evidence trial only tracked patients to 12 months, so anything beyond that comes from observational follow-up rather than controlled data. Real-world studies put one-year UTI-free rates at 33-78%.

Is MV140 the same as Uromune?

Yes. MV140 is the research code used in trial papers. Uromune is the commercial brand name from Madrid-based manufacturer Inmunotek. Both refer to the same sublingual polybacterial vaccine containing inactivated E. coli, Klebsiella pneumoniae, Proteus vulgaris, and Enterococcus faecalis in equal parts.

Can men take MV140 for recurrent UTI?

The Phase 3 NEJM Evidence trial enrolled women only. However, the 9-year EAU follow-up included 17 men alongside 72 women, and the results did not differ meaningfully by sex. UK and Australian special-access programs do prescribe to men with recurrent UTI, but the formal indication and trial evidence remain heavily female-skewed.

Can I get MV140 in Australia or the United States?

In Australia, MV140 is available under TGA Category C of the Special Access Scheme, meaning any doctor can prescribe it but must notify the TGA within 28 days of supply. In the US, it is not FDA-approved and not available outside of clinical trials. Spain, Mexico, and the Dominican Republic have full approval. The UK supplies it on a named-patient basis through specialists.

What are the side effects of the MV140 vaccine?

Mild and predominantly local. Across more than 17,000 documented treatment courses since 2010, no major safety signals have been reported. Less than 2% of patients experience mouth tingling, mild gastrointestinal upset, or transient warmth at the spray site. Rare events include mucosal swelling and allergic skin reactions. The Phase 3 trial recorded fewer total adverse events in the 6-month vaccine arm than in placebo.

How much does the MV140 vaccine cost?

In Australia, a 3-month course runs roughly AUD 400-600 depending on pharmacy markup. In the UK, named-patient prescriptions through private urology typically cost £400-£600. Health economic analyses estimate the vaccine saves money over 12-24 months by cutting GP visits by 68% and antibiotic costs by 70%, but the upfront cost is out-of-pocket in most jurisdictions because no public insurer reimburses it.

MV140 UTI Vaccine: 54% Still UTI-Free at 9 Years

Three UTIs a year was the threshold. Below that, you got antibiotics on demand. Above it, you became a “recurrent” case and your options narrowed: prophylactic antibiotics with resistance creeping in, methenamine hippurate if you were lucky, cranberry if your doctor was not paying attention.

The MV140 sublingual UTI vaccine sits awkwardly inside this picture. It has Phase 3 randomised data published in NEJM Evidence, 9-year follow-up presented at the European Association of Urology Congress in Paris last year, and full regulatory approval in Spain, Mexico, and the Dominican Republic. It also has no FDA approval, no European Medicines Agency authorisation, and a name almost no GP outside Madrid recognises.

That gap, between the data and the regulatory pace, is the real story.

Key Takeaways

The 2022 NEJM Evidence Phase 3 trial (n=240 women) found 56-58% of MV140 recipients UTI-free at 9 months versus 25% on placebo (p<0.001) [1]
A 9-year follow-up presented at EAU 2024 (n=89, including 17 men) found 54% remained UTI-free, mean 4.5 years free of infection [2]
The vaccine is a sublingual spray containing four whole-cell inactivated bacteria (E. coli, K. pneumoniae, P. vulgaris, and E. faecalis), taken twice daily for 3 months
Available in Australia via TGA Special Access Scheme Category C; in the UK via named-patient prescriptions; not available in the United States
Cost out-of-pocket in most countries, but cuts GP visits ~68% and antibiotic use ~70% in real-world data

What the Phase 3 Trial Found

The strongest controlled evidence comes from Lorenzo-Gómez and colleagues, published in NEJM Evidence in 2022 [1]. Two hundred and forty women, aged 18-75, all with at least three UTIs in the previous year, were randomised across Spanish and UK sites into three arms: MV140 for 3 months, MV140 for 6 months, or placebo for 6 months. Then everyone was followed for a year.

The headline numbers:

Arm	n	UTI-free at 9 months	Median UTIs	Median days to first UTI
MV140, 3 months	77	55.7%	0	275
MV140, 6 months	75	58.0%	0	275
Placebo, 6 months	78	25.0%	3	48

A 275-day median to first UTI versus 48 days. That gap is what makes the trial more than a statistical curiosity. For a woman who normally cycles through 3-4 UTIs a year, almost a calendar year between episodes is a real change in life rather than a slight tilt in the numbers.

Two points worth holding onto. First, the longer 6-month course did not produce a meaningfully bigger effect than the 3-month course, which is why guidelines in Spain and the UK have settled on 3 months as standard. Second, adverse events were actually lower in the 6-month vaccine arm (48 events) than in placebo (81 events), which is not how most vaccine trials read.

Why 9-Year Data Changes the Conversation

Phase 3 efficacy at 12 months is one thing. Durability is another. The follow-up that landed at the 2024 European Association of Urology Congress in Paris tracked a separate cohort, originally enrolled at Royal Berkshire NHS Foundation Trust in the UK [2].

Eighty-nine patients. Seventy-two women, 17 men. Mean follow-up close to a decade. The headline result: 54% of patients had not had a single UTI in the nine years since their original 3-month course. Mean time UTI-free was 4.5 years.

A clean caveat first. This was a single-centre observational follow-up, not a randomised trial. There is no placebo arm at 9 years. Patients who responded badly to MV140 or had early breakthrough infections may have been lost to follow-up at higher rates than responders, which would bias the result upward. The presentation has not yet been published as a peer-reviewed paper.

But even with those qualifiers, the durability is striking. Most non-antibiotic UTI prevention options (cranberry, D-mannose, probiotics, vaginal estrogen) produce benefits that wash out within 12-18 months of stopping. A bacterial vaccine that holds for half a decade in roughly half of recipients is a different class of result.

How a Bacterial Spray Trains Your Bladder’s Immune System

The vaccine contains four whole-cell inactivated bacteria, in equal parts: Escherichia coli (the cause of ~80% of UTIs), Klebsiella pneumoniae, Proteus vulgaris, and Enterococcus faecalis. Heat-killed. Suspended in glycerol with sodium chloride, pineapple flavouring, and water [3].

Two sprays under the tongue, every morning, for three months. That is the entire regimen.

Sublingual delivery matters here. The mucosal lymphoid tissue under the tongue connects, immunologically, to mucosal tissue throughout the body, including the urogenital tract. Mouse studies tracking the response found both systemic IgG and mucosal IgA responses, plus Th1 and Th17 cellular responses, with measurable infiltration of immune cells into the bladder wall after challenge with uropathogenic E. coli [4].

In plain terms: the immune system learns to recognise the four most common UTI pathogens at the mucosal surface, then deploys faster the next time a real bacterium arrives. It is not sterilising immunity. Vaccinated patients can still get UTIs. But the response is quicker and the infection burden is lower.

The interesting design choice is using whole inactivated bacteria rather than a protein-subunit or mRNA approach. Whole-cell vaccines induce broader, less targeted responses. That is exactly what you want when the pathogen population is heterogeneous and changes strain often, as uropathogenic E. coli does.

The Real-World Studies, Graded Below the RCT

Outside the Phase 3 trial, a stack of observational studies has accumulated since 2010. None is as clean as Lorenzo-Gómez 2022, but several are worth knowing.

A 2024 prospective real-life study published in Pathogens tracked outcomes in routine clinical use. After 12 months, 38% of patients were entirely UTI-free, 34% had 1-2 episodes, and 28% had 3 or more. The mean reduction was 3.2 UTI episodes per year per patient [5].

A larger cohort study of 1,104 women treated with Uromune in Spain reported similar reductions in episode frequency and antibiotic prescriptions over 24 months [6]. A 2024 literature review pulled together eight studies covering more than 2,200 patients and concluded the safety profile is favourable, but flagged that controlled evidence outside the single Phase 3 trial is thin [7].

A North American clinical experience series published in the Canadian Urological Association Journal in 2024 described early access program results and largely matched the European efficacy numbers. The same year, secondary analyses of the Phase 3 data showed quality-of-life gains on SF-36 scoring that began at 3 months and peaked at 12 months, with the vaccine arm reporting fewer days of restricted activity and fewer GP visits [8].

So the picture is: one strong RCT, two single-arm observational series of decent size, and one 9-year follow-up still in conference-presentation form. Compared with the evidence stack behind cranberry (a Cochrane review of 50 trials) or methenamine hippurate (the ALTAR non-inferiority RCT), MV140 has fewer pieces. The Phase 3 data is just stronger than anything in those alternative stacks.

MV140 vs Cranberry, Methenamine, and Antibiotic Prophylaxis

Where does it sit next to the other options a doctor might actually offer?

Option	Strongest evidence	Typical UTI reduction	Course	Main downside
MV140 (Uromune)	1 RCT, 9-yr follow-up	~50% UTI-free at 1 year, ~54% at 9 years	3 months, then nothing	Not approved in the US; out-of-pocket cost
Methenamine hippurate	ALTAR RCT, non-inferior to antibiotics	~50% reduction in episodes	Ongoing daily, indefinite	Daily dosing forever
Antibiotic prophylaxis	Strong (gold standard)	~85% reduction while on it	Daily for 6-12 months	Resistance, microbiome damage
Cranberry (PACs ≥36mg)	Cochrane 2023, 50 trials	~26% reduction overall	Daily indefinite	Many products underdosed
Vaginal estrogen (postmenopausal)	Multiple RCTs	~50-75% reduction	Twice weekly forever	Only for postmenopausal women
D-mannose	Mixed (recent RCTs negative)	~10-30% reduction	Daily indefinite	Evidence quality lower than thought

The standout feature of MV140 is not effect size — antibiotic prophylaxis still wins on raw efficacy. It is the duration profile. Three months of dosing, then nothing, with effect persistence measured in years rather than weeks. No other option on the list has that shape.

For comparison: stopping methenamine usually means UTIs return within a few months. Stopping daily antibiotics means resistant breakthroughs are common. Stopping cranberry erases the modest benefit immediately. MV140 is the only intervention where the protective effect outlasts the treatment by a wide margin.

Why It’s Still Not FDA-Approved After 14 Years

MV140 has been in clinical use in Spain since 2010. The 9-year follow-up patients started dosing in 2015. Yet the FDA approval pathway is still active rather than complete.

Three reasons.

The first is that early-phase trials were conducted entirely in Europe, and the FDA does not automatically accept foreign clinical data for approval. A US-based Phase 3 trial is generally required, and the multicentre Australian/US confirmatory study has been the bottleneck. Recruitment in that trial has been slower than expected.

The second is regulatory category. MV140 is not technically a “vaccine” in the FDA sense. It does not produce sterilising immunity against a defined pathogen, and the indication is prevention of an infection caused by multiple species rather than one. The FDA has historically struggled with polybacterial sublingual products in this grey zone between vaccine and bacterial lysate.

The third is commercial. Inmunotek is a Spanish company without the lobbying or regulatory affairs infrastructure of a large pharma player. The FDA pathway for a sublingual polybacterial product in a non-fatal indication is expensive and slow without major sponsor backing. Locus Biosciences pushed phage therapy for UTI into Phase 3 in a fraction of the time because it had VC funding and regulatory horsepower behind it.

The practical consequence: 14 years after first patient dosing, US patients can access MV140 only through clinical trials, while their UK and Australian counterparts pay privately through special-access schemes.

How to Actually Get It (Australia, UK, US)

Australia. The TGA reclassified Uromune to Category C of the Special Access Scheme in 2024, which means any registered doctor can prescribe it as an unapproved therapeutic good [9]. The doctor must notify the TGA within 28 days of supply via the SAS Category C online form. Cost is typically AUD 400-600 for a 3-month course, paid out-of-pocket. Chronic UTI Australia maintains a list of GPs and urologists familiar with the prescribing process.

United Kingdom. Available via “named-patient” prescription through a private urologist or specialist GP. The drug is technically unlicensed, so NHS supply is rare and almost always via specialist referral. The Urology Partnership and similar private clinics have established protocols. Cost is typically £400-£600 for the 3-month course.

United States. Not FDA-approved. The only legal route in the US is enrolment in an active clinical trial. The Australian-led multicentre trial accepts US patients at some sites. Compassionate use through some hospital programs is possible case-by-case but uncommon.

Other countries. Approved in Spain, Mexico, and the Dominican Republic. Available via Special Access programs in 26 countries total, according to Inmunotek’s own count. Canada’s Health Canada review is reportedly in late stages but no decision has been announced.

Treating the vaccine as an experimental option that needs paperwork rather than as standard care is the honest summary. That picture may change in 2-3 years, but it is still the picture today.

What MV140 Won’t Fix

The honest case against. Three things this vaccine is not.

First, it is not a treatment for an active UTI. The Phase 3 trial excluded patients with current symptoms. The vaccine takes weeks to build a meaningful mucosal response, which means it does nothing for a UTI you have right now. If you start MV140 mid-flare, you still need antibiotics to clear the active infection.

Second, it is not effective against pathogens outside the four covered species. Most UTIs in healthy women are E. coli (~80%), with the other three species covering most of the remainder, so the spectrum match is good. But complicated UTI, catheter-associated UTI, or infection with Pseudomonas, Candida, or unusual gram-negatives is outside what MV140 was designed for.

Third, the 9-year durability data still has selection bias baked in. Patients who did poorly on MV140 are less likely to have returned for follow-up, and the cohort is small. A peer-reviewed paper with proper attrition reporting may revise the 54% number down.

And one more, smaller point. Real-world studies show roughly a quarter of patients still have 3+ UTIs in the year after their course. For that quarter, MV140 simply did not work. There is no validated biomarker that predicts who will respond and who will not.

Red Flags to Watch For

If you start MV140 and develop a UTI during the 3-month dosing course, that does not mean the vaccine has failed. Immune responses take time to mature, and breakthrough infections in months 1-2 are normal. Treat the active infection with antibiotics and continue the spray course as planned.

A more concerning pattern is no measurable change after the full course completes. If you finish 3 months of MV140 and your next year matches your previous one (same frequency, same severity), that is the signal to revisit other options rather than start a second course. Repeat courses are sometimes prescribed off-label, but the evidence supporting them is thin.

Stop the vaccine and see a doctor if you develop unexpected mucosal swelling, breathing difficulty after spray, or a persistent rash. These reactions are rare (well under 1%) but real. The first dose can be taken in a clinic if anaphylaxis history is a concern.

And the basic one: blood in urine, flank pain, fever, or symptoms that change pattern unexpectedly. None of these are vaccine reactions. They are signals to investigate for upper-tract infection, stones, or other causes the vaccine cannot address.

Questions People Keep Asking

Will the MV140 vaccine work if I have interstitial cystitis, not bacterial UTI?

A 2024 secondary analysis of the Phase 3 trial looked at patients who turned out to have features of interstitial cystitis / bladder pain syndrome alongside their recurrent UTI [10]. The results were genuinely interesting. A subset of patients diagnosed with IC actually had hidden uropathogenic infection that the vaccine helped clear, with symptom improvement following. But the vaccine is not designed for inflammatory non-infectious bladder disease, and the IC subgroup result is hypothesis-generating rather than guidance.

Can MV140 replace prophylactic antibiotics?

In the Phase 3 trial, vaccine recipients used far fewer antibiotics over 12 months than placebo recipients. In real-world cohorts, antibiotic use drops by roughly 70%. For patients who want to escape continuous prophylactic antibiotic regimens, MV140 is the strongest non-antibiotic option with evidence behind it. The honest framing is “complement and gradually replace” rather than “stop your prophylaxis and start the spray on day one.”

Does the vaccine cover ESBL-producing or carbapenem-resistant E. coli?

The vaccine response is to bacterial surface antigens, not to enzymes that confer antibiotic resistance. So in principle, yes. An ESBL-producing E. coli and a sensitive E. coli present similar mucosal targets to the immune system. The Phase 3 trial did not stratify outcomes by resistance pattern, but observational reports from Spain note that the vaccine appears to maintain efficacy against multi-drug-resistant strains.

Is there a similar oral UTI vaccine I can get in the US right now?

Yes. Uro-Vaxom (also known as OM-89), an oral lysate of 18 E. coli strains, has been used in Europe for decades. It is also unapproved in the US. The evidence behind Uro-Vaxom is older and less impressive than MV140’s. Modest UTI reduction in randomised trials, no 9-year durability data. It is sometimes available through compounding pharmacies in the US on a case-by-case basis.

Do I need to take MV140 forever to keep the benefit?

No. The dosing schedule is 3 months and done. Re-dosing has been studied in some patients who broke through after 12-24 months, with mixed results. The 9-year data showing 54% protection comes from patients who took one 3-month course, full stop.

How is MV140 different from getting a flu shot every year?

Mechanism similar: train the immune system using inactivated pathogen. But the route differs (sublingual vs intramuscular), the schedule differs (one 3-month course vs annual), and the target population differs (recurrent UTI patients only vs general public). MV140 is closer to allergy desensitisation in delivery model and closer to a vaccine in immune effect.

The Verdict at 14 Years

MV140 sits in an awkward but interesting position. The Phase 3 data is strong by the standards of non-antibiotic UTI prevention. The 9-year follow-up suggests genuine durability rather than a brief signal that fades. The safety profile across 17,000+ documented courses is clean.

What it lacks is approval in the country that drives global pharma uptake. Until the US Phase 3 readouts arrive (likely 2027 or 2028), MV140 will remain the “thing people in the UK and Australia talk about” rather than “the new prevention standard.” For Australian patients with recurrent UTI who have run through cranberry, methenamine, and antibiotic prophylaxis, asking your GP about SAS Category C access is a reasonable conversation right now. For US patients, the next 2-3 years are the waiting room.

References

Lorenzo-Gómez MF, Foley S, Nickel JC, et al. Sublingual MV140 for prevention of recurrent urinary tract infections. NEJM Evidence. 2022;1(4):EVIDoa2100018. PubMed
Yang B, et al. Long-term efficacy of MV140 sublingual vaccine in recurrent UTI: 9-year follow-up. Presented at European Association of Urology Congress 2024, Paris. Conference summary
Inmunotek. Uromune product monograph. Madrid, Spain. Manufacturer page
Carrasco-Yepez M, et al. MV140 mucosal bacterial vaccine improves uropathogenic E. coli clearance in an experimental model of urinary tract infection. Frontiers in Immunology. 2023. PubMed
Lorenzo-Gómez MF, et al. Immunoprophylaxis with MV140 is effective in the reduction of urinary tract infections: a prospective real-life study. Pathogens. 2024. PubMed
Yang B, et al. Immunoactive prophylaxis protocol of uncomplicated recurrent UTI in a cohort of 1104 women treated with Uromune vaccine. 2024. PubMed
Various. Current evidence on safety, efficacy and efficiency of sublingual vaccine Uromune in prevention of recurrent UTI: a literature review. Pathogens. 2025;15(1):42. Open access
Lorenzo-Gómez MF, et al. Reducing recurrent UTIs in women with MV140 impacts personal burden of disease: secondary analyses of a randomized placebo-controlled efficacy study. 2024. PubMed
USANZ. Uromune for UTIs, TGA Category C update. January 2025. USANZ announcement
Secondary analysis of interstitial cystitis/bladder pain syndrome patients enrolled in a recurrent UTI prevention study. 2024. PubMed